-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Today, Roche announced that the Huntington’s disease trans-nucleic acid therapy tominersen (formerly known as IONIS-HTTRx, RG6042) acquired from Ionis has been suspended in the Phase III clinical GENERATION HD1 trial.
Drug source analysis
Drug source analysisHuntington's disease was first discovered in 1872 by a doctor called Huntington's disease.
Huntington's disease usually occurs in the adulthood of the patient.
Many rare genetic diseases appear in childhood, such as SMA, but some also occur in young adults.
These rare diseases used to be the domain of small biopharmaceutical companies, but with the soaring price of rare disease drugs and the increase in the efficacy requirements of the payment department, large pharmaceutical companies have also entered these fields.